Eradivir Secures Investment for Advancing Antiviral Therapeutics

Eradivir clinches investment for developing lead antiviral therapeutic EV25 and advancing molecule EV148 for respiratory syncytial virus treatment.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here